The Effects of Nitric Oxide for Inhalation on the development of chronic lung disease in pre-term infants. - INOT-27

INO Therapeutics0 个研究点目标入组 800 人开始时间: 2005年2月23日最近更新: 2019年6月30日

适应症

试验速览

暂无简介。

•The patient must meet the following criteria:
•Inborn preterm infants 24+0 weeks–28+6 days weeks gestational age (defined by first trimester ultrasound or if not available based on the last menstrual period) who
•requires the use of surfactant within 24 hours of birth, (either prophylactically or for
•signs of developing respiratory distress), or who requires the use of CPAP (FiO2 =
•0.30 and mean airway pressure = 4cm H2O) within 24 hours of birth in order to
•maintain an SpO2 = 85%.
•Informed consent of the parent or legal guardian.
•CPAP = Continuous Positive Airway Pressure
•SpO2 = Oxygen saturation by pulse oximeter
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•The patient will be excluded from enrollment if any of the following are true:
•Outborn infants.
•Infants = 29 weeks gestational age.
•Infants with birth weight <500 grams.
•Infants requiring FiO2 >0.5 to maintain SpO2 >85%, on a sufficient mean airway
•pressure (e.g., > 8 cm H2O on CMV) in order to achieve adequate chest inflation (8-9
•ribs on Chest X-ray) two hours after the proper administration of exogenous
•surfactant.
•Any suspected congenital heart disease other than patent ductus arteriosus or atrial septal defect.
•Any infant with suspected lung hypoplasia associated with congenital diaphragmatic hernia
•Any infant with severe bleeding and/or coagulation abnormalities at high-risk of
•diathesis, e.g., platelet <50,000/mm3, fibrinogen <0.5 g/L, other clotting factors <10%.
•Any infant in whom a decision has been made not to provide full treatment, e.g.,
•chromosomal abnormalities, severe multiple abnormalities, severe birth asphyxia, etc.
•Use of another investigational drug or device before or during the active study period.
•CMV = Controlled Mechanical Ventillation.
•FiO2 = Fraction of inspired oxygen concentration

发起方

INO Therapeutics